
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is positioned for significant growth, driven by key momentum factors such as Medicare expansion, which is expected to enhance coverage and patient access through clinical data expected in 2026, and additional wins in the NIT segment that will broaden the number of covered lives. The company's innovative product pipeline, including the improved G7 sensor and the introduction of SmartBasal, indicates strong potential for increasing adoption and usage among diabetic patients. With operational efficiency improvements leading to better gross margins and projected revenue growth in the mid-teens alongside EPS growth exceeding 20% through 2028, DexCom's financial outlook remains robust.
Bears say
DexCom's financial performance indicates a concerning trend with hardware revenue declining sharply by 31% year-over-year, while overall revenue guidance for FY26 falls slightly short of market expectations, suggesting potential challenges ahead. Additionally, the anticipated sequential revenue decline of 6-7% in Q1 2026 highlights a decelerating growth trajectory, exacerbated by changes in the company's sales seasonality and an increasing reliance on pharmacy distribution. Compounding these issues, the company's inability to substantively improve its competitive standing amidst recent US growth slowdowns and execution difficulties raises doubts about the stock's valuation compared to its peers.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares